Innovent registers Phase III trial testing sintilimab in rectal cancer total neoadjuvant therapy
Innovent Biologics registered a Phase III study adding sintilimab to chemoradiotherapy for locally advanced rectal cancer, with start targeted for November 2026.
Innovent Biologics had one registry item post this week, a new Phase III oncology trial.
- Innovent registered "Sintilimab Combined With Long-Course Concurrent Chemoradiotherapy Followed by Capeox Consolidation Chemotherapy" (NCT07917468) for patients with mismatch repair-proficient or microsatellite stable/low instability locally advanced rectal cancer. This is a randomized, double-blind, controlled, Phase III clinical study to evaluate the efficacy and safety of sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy, which is planned to enroll 500 subjects with locally advanced rectal cancer.1 The study is listed as not yet recruiting, with an estimated start date of 2026-11-25, and its primary outcome is event-free survival.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.